Kathryn B. Metcalf *

Research Article

Does Aspirin Provide Adequate Chemoprophylaxis for Venous Thromboembolic Events in Operative Pelvic and Acetabular fractures?

Kathryn B. Metcalf * MD, Jerry Y. Du MD, Corina C. Brown MD, Robert J. Wetzel MD, John K. Sontich MD, Joshua K. Napora MD, George Ochenjele MD

University Hospitals Cleveland Medical Center Case Western Reserve University School of Medicine Department of Orthopaedic Trauma Surgery, Cleveland, Ohio 11100 Euclid Ave Cleveland, Ohio 44106.

*Corresponding Author: Kathryn B. Metcalf, University Hospitals Cleveland Medical Center Case Western Reserve University School of Medicine Department of Orthopedic Trauma Surgery, Cleveland, Ohio 11100 Euclid Ave Cleveland, Ohio 44106.

Received Date: January 10, 2022; Accepted Date: January 31, 2022; Published Date: February 04, 2022

Citation: Kathryn B. Metcalf., Jerry Y. Du., Corina C. Brown., Robert J. Wetzel., John K. Sontich, et all (2022). Does Aspirin Provide Adequate Chemoprophylaxis for Venous Thromboembolic Events in Operative Pelvic and Acetabular fractures? *J. Clinical Orthopedics and Trauma Care*, 4(3); DOI:10.31579/2694-0248/027

Copyright: © 2022 Kathryn B. Metcalf, This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Pelvic and acetabular fractures often result from high-energy mechanisms and represent unique treatment challenges. These fractures commonly occur with concomitant polytraumatic injuries and in the setting of significant medical comorbidities. Pelvic-acetabular trauma injuries are complex, frequently require surgical intervention, and carry a high risk of complications with sequelae leading to poor patient outcomes and large economic health-care burdens.

Keywords: venous thromboembolism; pelvic acetabular

Introduction

Pelvic and acetabular fractures often result from high-energy mechanisms and represent unique treatment challenges. These fractures commonly occur with concomitant polytraumatic injuries and in the setting of significant medical comorbidities. Pelvic-acetabular trauma injuries are complex, frequently require surgical intervention, and carry a high risk of complications with sequelae leading to poor patient outcomes and large economic health-care burdens. [1,2]

Development of a venous thromboembolism (VTE) following surgical fixation of pelvic and acetabular fractures is a serious and sometimes lifethreatening complication. Previous studies of these complicated injuries have elucidated independent risk factors that predispose the patient to increased risk of PE and deep vein thrombosis (DVT) such as age, associated injuries, injury severity, and time to surgery. [3-6] Additionally, VTE events are associated with significant economic implications. One recent study in hip fracture patients demonstrated that VTE events were an independent reason for a 2-fold increase hospital length of stay and cost. [7] With rates of VTE ranging from 10-30%, coupled with a small but significant rate of pulmonary embolism (PE) in pelvic and acetabular fractures, prevention strategies are critical. [3-5,8,9] In fact, the risk of post-operative VTE is even greater in those fracture patients who receive no chemoprophylactic treatment, with reported rates as high as 40-68%.[10-13]

Although VTE is a known complication, there is limited data and no consensus on optimal thromboprophylactic agents and algorithms following operative fixation of pelvic and acetabular fractures. [8,14,15]

There is high variability among different institutions. It is often debated if aspirin is an effective anticoagulation agent that provides adequate thromboprophylaxis in the setting of these complex injuries. The different mechanisms of action of agents play a role in this controversy of optimal thromboprophylaxis. Where aspirin acts via anti-platelet aggregation, the more traditionally used agents, enoxaparin and heparin, activate and accelerate antithrombin III (AT), inactivating thrombin and factor Xa. Although a multitude of anticoagulants are used in the prevention of VTE, the associated risk of bleeding or hematoma development is another important consideration in choice of thromboprophylactic agent. Despite the extensive reports on the effectiveness of various anticoagulants in total joint arthroplasty literature, [16-19] very little data exists regarding these thromboprophylactic medications in the setting of fracture patients, particularly pelvic and acetabular fractures. In fact, to the author's knowledge no studies evaluating the efficacy of aspirin compared to enoxaparin or heparin in preventing VTE in these complicated injuries is described in the literature.

The objective of this study is to evaluate the efficacy of aspirin in prevention of VTE, including both DVT and PE, compared to the shortacting injectable anticoagulants, enoxaparin and heparin, following operative fixation of pelvic and acetabular fractures. A secondary aim was to evaluate the incidence of hematoma formation between anticoagulants. We anticipated that aspirin would be an efficacious VTE prophylaxis agent and have a lower rate of hematoma development compared to other agents.

Methods

After institutional review board (IRB) approval, a retrospective chart review of patients who sustained pelvic ring and acetabular fractures treated with operative fixation was performed. Current Procedural Terminology (CPT) codes identified 163 pelvic or acetabular fractures managed operatively between 2015-2020 at our level 1 trauma center. Patients were included if the were \geq 18 years of age, received aspirin, enoxaparin, or heparin as their primary anticoagulant, and had a minimum of 6 weeks post operative follow up, for injury or surgically related VTE events occur within a 6 week threshold, as nearly all post-operative VTE occur early within this timeframe. [20,21] Patients were excluded if they were <18 years of age (4), had a pathologic fracture (2), had undergone previous operative fixation of pelvis or acetabulum (4), received warfarin or a newer oral anticoagulant (6), or lacked 6 week follow up (3).

Three fellowship-trained traumatologists treated all fractures. Surgical approach was dictated by fracture pattern and surgeon preference. The primary team determined treatment with aspirin, enoxaparin, or heparin. Patient demographics, medical comorbidities, and post-operative weight bearing status were accounted for across groups and normalized in a multivariate analysis.

The primary outcome measures were development of DVT or PE within a 6-week post-operative period. Hematoma development was considered a secondary outcome. Hematoma formation was defined by evidence on computed tomography (CT) and a drop in hemoglobin. Patients were treated with aspirin 81 milligrams (mg) twice a day, enoxaparin 40mg daily, or 5,000 units heparin twice a day. Mechanical prophylaxis of ambulation and sequential compressive devices (SCDs) were used in all patients. The rate of VTE and hematoma formation was compared between patients receiving aspirin and short-acting injectables, enoxaparin and heparin. Incidence of VTE and post-operative hematoma was evaluated between these groups.

Other variables reported to affect development of VTE were collected. Age, gender, time to surgery, type of anticoagulant, weight bearing status, past medical history including diabetes mellitus (DM), hypertension (HTN), chronic kidney disease (CKD), coronary artery disease (CAD), body mass index (BMI) smoking status, previous history of DVT, head trauma were assessed as potential risk factors of VTE. Trauma scores such as abbreviated injury scale (AIS) and injury severity scale (ISS), intensive care unit (ICU) length of stay (LOS), hospital LOS, and ventilator time were also assessed as potential confounders. Additionally, in this study both posterior (Kocher-Langerbeck) and anterior (anterior intrapelvic, Pfannenstiel, or ilio-inguinal) approaches were used and evaluated as confounding variables.

Statistical Analysis

Categorical variables are expressed as percentages and continuous variables are expressed as mean \pm standard deviation. Continuous variables were found to not be normally distributed by Kolmogorov-Smimov tests. Univariate analysis comparing incidence of confounding variables and complications was performed using Mann-Whitney U test or chi-squared/fisher's exact tests as appropriate.

Multivariate binary logistic regression models were created for complications that were significantly different based on surgical approach on univariate analysis. Confounding variables with p<0.10 were included for analysis. An α =0.05 was considered statistically significant. Statistical analysis was performed using SPSS (SPSS 25.0, IBM, Armonk, NY).

Results

There were 144 pelvic and acetabular fractures that met inclusion criteria. Mean age was 42.2 ± 17.1 years. There were 95 males (66.0%) and 49 females (34.0%). There were 6 patients (4.2%) that developed DVT and 5 patients (3.5%) that developed PE. Two patients developed both (1.4%). There were 54 patients treated with aspirin (37.5%) and 90 patients treated with heparin or enoxaparin (62.5%). On univariate analysis of complications, there was a significantly lower incidence of hematoma formation in the aspirin cohort (n=3, 5.6% vs. n=19, 21.1%, p =0.015) (Table 1).

Complications	Enoxaparin/ Heparin	Aspirin	Relative Risk	95% Confidence Interval	P-value		
Primary Complications of Interest							
Deep Vein Thrombosis	4 (4.4%)	2 (3.7%)	0.935	0.523-1.670	>0.999		
Pulmonary Embolus	3 (3.3%)	2 (3.7%)	1.043	0.504-2.158	>0.999		
Hematoma	19 (21.1%)	3 (5.6%)	0.674	0.539-0.843	0.015		
Transfusion	17 (18.9%)	6 (11.1%)	0.816	0.615-1.083	0.217		
Secondary Complications of Interest							
Infection	6 (6.7%)	3 (5.6%)	0.933	0.577-1.509	>0.999		
Mortality	1 (1.1%)	2 (3.7%)	1.894	0.380-9.429	0.556		

Table 1: Univariate Analysis of Complications

There were no differences in incidence of DVT, PE, or transfusion between cohorts. Similarly, there were no differences in the incidences of infection or mortality. On univariate assessment of potential demographic and comorbidity confounders, the aspirin cohort was found to have a lower incidence of obesity (n=13, 24.1% vs. n=40, 46%, p=0.009) (Table 2).

					aan yn Bin			
Potential Confounder	Enoxaparin/ Heparin	Aspirin	Relative Risk	95% Confidence Interval	P- value			
Demographic								
Age	40.2±16.0	45.5±18.5	-	-	0.127			
<u>_</u>								
		Gender						
Male	55 (61.1%)	40 (74.1%)	0.550	0.262.1.155	0.112			
Female	35 (38.9%)	14 (25.9%)	0.550	0.262-1.155				
	Co	omorbidities						
Smoking	30 (33.3%)	26 (48.1%)	1.273	0.959-1.688	0.077*			
Obesity	40 (46.0%)	13 (24.1%)	0.708	0.552-0.907	0.009			
Hypertension	24 (26.7%)	16 (29.6%)	1.058	0.790-1.416	0.701			
Diabetes			1.281	0.772-2.127	0.273			
Chronic Kidney Disease	1 (1.1%)	0 (0%)	-	-	>0.999			
Coronary Artery Disease	2 (2.2%)	4 (7.4%)	1.913	0.613-5.973	0.197			
Prior Deep Vein Thrombosis	0 (0%)	1 (1.9%)	-	-	0.375			

Table 2: Univariate Analysis of Demographics and Comorbidities

On univariate analysis of potential injury and perioperative confounders, the aspirin cohort was found to have lower ISS (11.0 ± 7.9 vs. 15.6 ± 10.4 , p=0.010), lower incidence of ICU stay (n=10, 22.7% vs. n=37, 51.4%, p=0.002), less weight bearing restrictions (p=0.001), and received more

heterotopic ossification prophylaxis (p=0.031) (Table 3). Furthermore, there was no difference in rate of DVT or PE based on an anterior or posterior approach (Table 3).

Potential Confounder		Enoxaparin/ Heparin	Aspirin	Relative Risk	95% Confidence Interval	P-value		
Concurrent Injuries								
Head Injury		5 (5.6%)	1 (1.9%)	0.739	0.505-1.082	0.410		
Polyt	rauma	51 (56.7%)	24 (44.4%)	0.831	0.642-1.077	0.155		
			Severity	1	1			
Abbreviated Injury Scale		2.8±0.8	2.6±0.7	-	-	0.083*		
Injury Sev	verity Scale	15.6±10.4	11.0±7.9	-	-	0.010		
Vent	Ventilator		3 (6.8%)	0.698	0.535-0.911	0.063*		
Intensive Ca	Intensive Care Unit Stay		10 (22.7%)	0.644	0.489-0.849	0.002		
		Periopera	tive Details					
Delay ≥48 Hours from Admission		60 (68.9%)	40 (74.1%)	1.097	0.842-1.429	0.508		
	As Tolerated	5 (5.6%)	6 (11.1%)		-			
Weight Bearing Status	Partial	43 (47.8%)	40 (74.1%)					
	Nonweight Bearing	13 (14.4%)	4 (7.4%)	-		0.001		
	Transfers Only	29 (32.2%)	4 (7.4%)					
Heterotopic	Radiation	20 (22.2%)	21 (38.9%)					
Ossification prophylaxis	Indomethacin	4 (4.4%)	5 (9.3%)			0.031		

J. Clinical Or	thopaedics and Trauma	Care				Copy rights @	Kathryn B. Metcalf et.al.
	Surgical Approach	Anterior	25 (27.8%)	12 (22.2%)			
		Posterior	35 (38.9%)	29 (53.7%)			
		Lateral	8 (8.9%)	4 (7.4%)		-	0.464
		Percutaneous	17 (18.9%)	8 (14.8%)			
		Combined	5 (5.6%)	1 (1.9%)			

Table 3: Univariate Analysis of Injury and Perioperative Variables

On multivariate analysis of major complications, accounting for the confounding variables found on univariate analysis, there were no significant differences incidence of VTE between aspirin and enoxaparin/heparin cohorts (Table 4).

Complication	Adjusted OR	95% Confidence Interval	P-value
DVT	3.377	0.100-114.506	0.498
PE	10.174	0.177-585.710	0.262
Hematoma	0.139	0.015-1.315	0.085
Transfusion	0.687	0.146-3.234	0.635

Table 4: Multivariate Analysis of Complications Based on Anticoagulation

However, aspirin trended on significance as protective against postoperative hematoma formation (adjusted odds ratio [aOR]: 0.687, 95% Confidence Interval [CI]: 0.015-1.315, [p=0.085]).

Discussion

Several strategies exist to prevent venous thromboembolism (VTE) in operative pelvic and acetabular fractures, however the current literature lacks consensus on optimal thromboprophylaxis, particularly on the use of aspirin compared to other anticoagulant agents. This study suggests that there is no significant difference in the rate of VTE with aspirin compared to short-acting injectables enoxaparin and heparin and there is a trend towards a lower rate of hematoma associated with the use of aspirin.

Development of postoperative hematoma has been associated with an increased rate of surgical site infection (SSI). [22] Often patients suffering from pelvic trauma are polytraumatized patients and at high risk for complications. The reported rate of surgical site infections occur following operative fixation of pelvic and acetabular fractures is 5-8%.[23,24] The ability to limit infection and recognizing factors that may be protective in these patients is critical since infection and can greatly hinder the recovery of patients and add an unprecedented burden to the patient and the medical system.

Many patients with pelvic and acetabular fractures undergo a long stay in an ICU, are immobilized with weight bearing restrictions and have high ISS scores. Previous studies demonstrate that these factors are associated with increased development of VTE. [6,25] In this study these variables, while noted to be lower in the aspirin cohort, were controlled for in the multivariate analysis to eliminate their confounding effect. Thus, there was no evidence to indicate that aspirin was inferior to enoxaparin or heparin. This study suggests that aspirin provides adequate VTE chemoprophylaxis following operative fixation of pelvic and acetabular fractures.

In patients with pelvic and acetabular fracture, previous studies have noted that early initiation of VTE chemoprophylaxis is a significant preventative measure, [25] but its use must be balanced with the risk for bleeding and development of post-operative hematoma. With aspirin trending towards significance as protective against hematoma, this may represent a favorable option in the appropriate patients.

Additionally, there was no significant association in the risk of VTE events and the approach utilized for the pelvis or acetabulum fractures. We anticipated that the anterior approach would be a risk factor for VTE events due to mobilization and direct manipulation of great vessels that is often required. We theorized that there could be a potential risk that this could increased turbulence and thus increase the risk of a VTE event.

Auctores Publishing LLC – Volume 4(3)-027 www.auctoresonline.org ISSN: 2694-0248

However, this was not demonstrated in this study. Another recent study showed that this theoretical risk was not substantiated and that the rate of VTE was not increased in the anterior approach.⁶ Furthermore, this was a variable that was controlled for in the multivariate analysis. Regardless of approach aspirin appears to be an efficacious chemoprophylactic agent in patients with pelvic and acetabular fractures that undergo operative fixation.

Aspirin as an effective anticoagulation agent has been recognized in the total joint arthroplasty literature. [19] This study suggests that it is also an effective thromboprophylactic medication in pelvic and acetabular fractures and represents certain benefits for patients. The ease of administration compared to enoxaparin and heparin is a substantial consideration. Additionally, the relatively low cost of an over the counter medication is significant. These factors could potentially lead to increased patient compliance post-operatively.

This study is not without limitations. There are inherent limitations given the retrospective nature. Although it represents one of the larger cohorts of pelvic and acetabular fractures in the literature that reviews VTE prophylaxis, a larger population would be beneficial. With this small sample size that showed differences between groups such as less obesity, lower ISS, shorter ICU LOS and less restrictive weightbearing were analyzed using a multivariate regression model. However, a larger cohort examined prospectively would provide greater understanding of the optimal VTE prophylactic protocol. Furthermore, this study only examined aspirin compared to short-acting injectables, enoxaparin and heparin. However in there very few patients were excluded for receiving an alternative anticoagulation regimen for VTE prophylaxis, and thus this may not be a significant limitation. While this study suggests that aspirin is not inferior to other anticoagulants, larger randomized controlled trials are necessary to further determine the optimal anticoagulation agent to reduce the risk of both VTE and postoperative hematoma formation in operative pelvic and acetabular fractures.

Conclusion

This study suggests that aspirin is an acceptable method of VTE thromboprophylaxis with no inferior results to other common anticoagulants used in operative pelvis and acetabular fractures. In fact, aspirin is likely protective against hematoma formation in these injuries, making it potentially advantageous as hematoma increases infection risk and can lead to further complications in patient recovery.

Conflicts of Interest:

There are no conflicts of interest or sources of funding for any of the authors.

J. Clinical Orthopaedics and Trauma Care

Conflicts of Interest and Source of Funding:

Dr. Ochenjele is a paid consultant for Stryker.

Dr. Wetzel is a paid consultant for Stryker, Biocomposites Inc, Bone Solutions Inc, and Medical Advance and receives royalties from Innomed Inc.

References

- 1. Judet R, Judet J, Letournel E. Fractures of the acetabulum: classification and surgical approached for open reduction. Preliminary report. J Bone Joint Surg Am. 1964;46:1615-1646
- Burgess AR, Eastridge BJ, Young JW, Ellison TS, Ellison PS, Poka A, et al. Pelvic ring disruptions: effective classification system and treatment protocols J. Trauma. 1990;30(7):848-856.
- Wang P, Kandemir U, Zhang B, Wang B, Li J, Zhuang Y, et al. Incidence and risk factors of deep vein thrombosis in patients with pelvic and acetabular fractures. Clin Appl Thromb Hemost. 2019;25:1076029619845066. doi: 10.1177/1076029619845066.
- Sen RK, Kumar A, Tripathy S, Aggarwal S, Khandelwal N. Risk factors of venous thromboembolism in Indian patients with pelvic acetabular trauma. J Orthop Surg (Hong King). 2011;19(1):18-24.
- Arroyo W, Nelson KJ, Belmont PJ, Bader JO, Schoenfeld AJ. Pelvic trauma: what are the predictors of mortality and cardiac, venous, thrombo-embolic and infectious complications following injury? Injury. 2013;44(12):1745-1749.
- Ostrowka C, Bonhomme S, Jouffroy P, Riouallon G. Evaluation of venous thromboembolic complications in patients operated on for pelvic fracture. Orthop Traumatol Surg Res. 2018;104(6):917-9121.
- Trivedi NN, Abola MV, Kim CY, Sivasundaram L, Smith EJ, Ochenjele G. The incremental cost of inpatient venous thromboembolism after hip fracture surgery. J Orthop Trauma. 2020;34(4):169-173.
- Fishmann AJ, Greeno RA, Brooks LR, Matta JM. Prevention of deep vein thrombosis and pulmonary embolism in acetabular and pelvic fracture surgery. Clin Orthop Relat Res. 1994;(305):133-137.
- 9. Kim JW, Oh CW, Oh JK, Baek SG, Lee BJ, Hong HP, et al. The incidence and the risk factors of venous thromboembolism in Korean patients with pelvic or acetabular fractures. J Orthop Sci. 2014;19(3):471-477.
- Flavas DA, Megaloikonomos PD, Dimopoulos L, Mitsiokapa E, Koulouvaris P, Mavrogenis AF. Thromboembolism prophylaxis in orthopaedics: an update. EFORT Open Rev. 2018;3(4):136-148.
- 11. Geerts WH, Code KI, Jay RM, Chen E, Szalai JP. A prospective study of venous thromboembolism after major trauma. New Engl J Med. 1994;331(24):1601-1606.
- 12. Moed BR, Miller JR, Tabaie SA. Sequential duplex ultrasound screening for proximal deep venous thrombosis in asymptomatic patients with acetabular and pelvic fractures treated operatively. J Trauma Acute Care Surg. 2012;72(2):443-447.

- Sharma OP, Oswanski MF, Joseph RJ, Tonui P, Westrick L, Raj SS, et al. Venous thromboembolism in trauma patients. Am Surg. 2007;73(11):1173-1180.
- Slobogean GP, Lefaivre KA, Nicolaou S, O'Brien PJ. A systematic review of thromboprophylaxis for pelvic and acetabular fractures. J Orthop Trauma. 2009;23(5):379-384.
- 15. El-Daly I, Reidy J, Culpan P, Bates P. Thromboprophylaxis in patients with pelvic and acetabular fractures: a short review and recommendations. Injury. 2013;44(12):1710-1720.
- Zimlich RH, Fulbright BM, Friedman RJ. Current Status of Anticoagulation Therapy After Total Hip and Total Knee Arthroplasty. The Journal of the American Academy of Orthopaedic Surgeons. 1996;4(2):54-62.
- 17. Jacobs JJ, Mont MA, Bozic KJ, Della Valle CJ, Goodman SB, Lewis CG, et al. American Academy of Orthopaedic Surgeons clinical practice guideline on: preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty. The Journal of bone and joint surgery American volume. 2012;94(8):746-747.
- Barrack RL. Current guidelines for total joint VTE prophylaxis: dawn of a new day. The Journal of bone and joint surgery British volume. 2012;94(11 Suppl A):3-7.
- Bala A, Huddleston JI, 3rd, Goodman SB, Maloney WJ, Amanatullah DF. Venous thromboembolism prophylaxis after TKA: aspirin, warfarin, enoxaparin, or Factor Xa inhibitors? Clinical orthopaedics and related research. 2017;475(9):2205-2213.
- 20. Wilson D, Cook EA, McNally MA, Wilson HK, Yeates A, Mollan RA. Changes in coagulability as measured by thrombelastography following surgery for proximal femoral fracture. Injury 2001;32 (10):765-770.
- 21. Wilson D, Cooke EA, McNally MA Wilson HK, Yeates A, Mollan RAB. Altered venous function and deep vein thrombosis following proximal femoral fracture. Injury. 2002;33(1):33-39.
- 22. Sanchez-Ballester J, Smith M, Hassan K, Kershaw S, Elsworth CS, Jacobs L. Wound infection in the management of hip fractures: a comparison between low-molecular weight heparin and mechanical prophylaxis. Acta Orthop Belg, 2005;7(1):55-59.
- Ochenjele G, Reid KR, Castillo RC, Schoonover CD, Montalvo RN, Manson TT, et al. Predictors of unplanned reoperation after operative treatment of pelvic ring injuries. J Orthop Trauma. 2018;32(7);e245-250.
- 24. Cichos KH, Mahmoud KH, Spitler CA, Abdel Aal AMK, Osman S, McGwin G, et al. Risk factors for surgical site infection after operative fixation of acetabular fractures: is psoas density a useful metric? Clin Orthop Relat Res. 2020. doi: 10.1097/CORR.00000000001207.
- 25. Wang H, Chen W, Su Y, Li Z, Li M, Wu Z, et al. Thrombotic risk assessment questionary helps increase the use of thromboprophylaxis for patients with pelvic and acetabular fractures. Indian J Orthop 2012;46:413-419.



This work is licensed under Creative Commons Attribution 4.0 License

To Submit Your Article Click Here:

re: Submit Manuscript

DOI:10.31579/2694-0248/021

Ready to submit your research? Choose Auctores and benefit from:

- ➢ fast, convenient online submission
- > rigorous peer review by experienced research in your field
- rapid publication on acceptance
- > authors retain copyrights
- > unique DOI for all articles
- immediate, unrestricted online access

At Auctores, research is always in progress.

 $Learn\ more\ https://auctoresonline.org/journals/journal-of-thoracic-disease-and-cardiothoracic-surgery$